The Recovery of Factor VIII from Fresh-Frozen, Indated and Outdated Human Plasma

Summary

The availability of factor VIII concentrates is frequently a limitation in the management of classical hemophilia. Such concentrates are prepared from fresh or fresh-frozen plasma. A significant volume of plasma in the United States becomes “indated”, i. e., in contact with red blood cells for 24 hours at 4°, and is therefore not used to prepare factor VIII concentrates. To evaluate this possible resource, partially purified factor VIII was prepared from random samples of fresh-frozen, indated and outdated plasma. The yield of factor VIII protein and procoagulant activity from indated plasma was about the same as that from fresh-frozen plasma. The yield from outdated plasma was substantially less. After further purification, factor VIII from the three sources gave a single subunit band when reduced and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. These results indicate that the approximately 287,000 liters of indated plasma processed annually by the American National Red Cross (ANRC) could be used to prepare factor VIII concentrates of good quality. This resource alone could quadruple the supply of factor VIII available for therapy.

• References

• 1 Anderson H. 1975 American National Red Cross. personal communication.
• 2 James H. L, Wickerhauser M. 1972; Development of large-scale fractionation methods. Vox Sanguinis 23: 402.
• 3 Johnson A. J, Pert J. H, Lackner H, Wolf N, Rohde V, Eltringham L, Mantkoff M, McCall K. B, Westcott W, Perrotta J, Hyndman L. A. 1964; Studies on a fractionation method suitable for large-scale preparation of antihemophilic factor and evaluation of preliminary clinical results in vivo. Vox Sanguinis 9: 232.
• 4 Langdell R. D, Wagner R. H, Brinkhous K. M. 1953; Effect of antihemophilic factor on one-stage clotting tests. Journal of Laboratory and Clinical Medicine 41: 637.
• 5 Levine P. H. 1975; Delivery of health care in hemophilia. Annals of the New York Academy of Sciences 240: 201.
• 6 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. 1951; Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193: 265.
• 7 McKee P. A, Andersen J. C, Switzer M. E. 1975; Molecular structural studies of human factor VIII. Annals of the New York Academy of Sciences 240: 8.
• 8 Nilsson I. M. 1971. Haemorrhagic and Thrombotic Diseases. John Wiley and Sons; London.:
• 9 Newman J, Johnson A. J, Karpatkin M. H, Puzkin S. 1971; Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. British Journal of Haematology 21: 1.
• 10 Penick G. D, Brinkhous K. M. 1956; Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. American Journal of Medical Science 232: 434.
• 11 Pool J. G, Shannon A. E. 1965; Production of high-purity concentrates of antihemophilic globulin in a closed-bag system: Assays in vitro and in vivo. New England Journal of Medicine 273: 1443.
• 12 Rapaport S. I, Ames S. B, Mikkelsen S. 1959; The levels of antihemophilic globulin and proac-celerin in fresh and bank blood. American Journal of Clinical Pathology 31: 297.
• 13 Shapiro G. A, Andersen J. C, Pizzo S. V, McKee P. A. 1973; The subunit structure of normal and hemophilic factor VIII. Journal of Clinical Investigation 52: 2198.
• 14 Stengle J. M. 1975; The hemophiliac’s demand on blood resources: The magnitude of the problem. Annals of the New York Academy of Sciences 240: 155.